Molecular heterogeneity of localized prostate cancer: more different than alike
- PMID: 28529909
- PMCID: PMC5438201
- DOI: 10.21037/tcr.2017.02.17
Molecular heterogeneity of localized prostate cancer: more different than alike
Conflict of interest statement
Conflicts of Interest: ES Antonarakis has served as a paid consultant/advisor for Janssen, Astellas, Sanofi, Dendreon, ESSA, Merck, and Medivation. And JJ Tosoian has no conflicts of interest to declare.
References
-
- Fraser M, Berlin A, Bristow RG, et al. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol. 2015;33:85–94. - PubMed
-
- Yadav SS, Li J, Lavery HJ, et al. Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment. Urol Oncol. 2015;33:267.e1–13. - PubMed
-
- Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol. 1994;152:1709–13. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources